Stock Scorecard
Stock Summary for Nurix Therapeutics Inc (NRIX) - $10.94 as of 5/5/2025 8:47:40 PM EST
Total Score
9 out of 30
Safety Score
33 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for NRIX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NRIX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NRIX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NRIX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NRIX (33 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for NRIX
Financial Details for NRIX
Company Overview |
|
|---|---|
| Ticker | NRIX |
| Company Name | Nurix Therapeutics Inc |
| Country | USA |
| Description | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 2/28/2025 |
| Next Earnings Date | 7/9/2025 |
Stock Price History |
|
| Last Day Price | 10.94 |
| Price 4 Years Ago | 28.95 |
| Last Day Price Updated | 5/5/2025 8:47:40 PM EST |
| Last Day Volume | 525,663 |
| Average Daily Volume | 1,111,212 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Last Price to 52 Week Low | 33.74% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 32.04 |
| Sector PE | 37.03 |
| 5-Year Average PE | -9.39 |
| Free Cash Flow Ratio | 10.94 |
| Industry Free Cash Flow Ratio | 19.19 |
| Sector Free Cash Flow Ratio | 29.42 |
| Current Ratio Most Recent Quarter | 6.26 |
| Total Cash Per Share | 1.00 |
| Book Value Per Share Most Recent Quarter | 6.31 |
| Price to Book Ratio | 1.81 |
| Industry Price to Book Ratio | 7.60 |
| Sector Price to Book Ratio | 21.93 |
| Price to Sales Ratio Twelve Trailing Months | 15.50 |
| Industry Price to Sales Ratio Twelve Trailing Months | 101.19 |
| Sector Price to Sales Ratio Twelve Trailing Months | 28.34 |
| Analyst Buy Ratings | 10 |
| Analyst Strong Buy Ratings | 5 |
Share Statistics |
|
| Total Shares Outstanding | 76,236,000 |
| Market Capitalization | 834,021,840 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -34.47% |
| Reported EPS 12 Trailing Months | -2.79 |
| Reported EPS Past Year | -0.67 |
| Reported EPS Prior Year | -2.89 |
| Net Income Twelve Trailing Months | -208,402,000 |
| Net Income Past Year | -193,569,000 |
| Net Income Prior Year | -143,948,000 |
| Quarterly Revenue Growth YOY | 11.30% |
| 5-Year Revenue Growth | 11.88% |
| Operating Margin Twelve Trailing Months | -340.70% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 75,916,000 |
| Total Cash Past Year | 109,997,000 |
| Total Cash Prior Year | 54,627,000 |
| Net Cash Position Most Recent Quarter | 75,916,000 |
| Net Cash Position Past Year | 109,997,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 526,993,000 |
| Total Stockholder Equity Prior Year | 200,493,000 |
| Total Stockholder Equity Most Recent Quarter | 480,917,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -201,594,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.64 |
| Free Cash Flow Past Year | -181,857,000 |
| Free Cash Flow Prior Year | -89,766,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.28 |
| MACD Signal | -0.63 |
| 20-Day Bollinger Lower Band | 7.89 |
| 20-Day Bollinger Middle Band | 15.44 |
| 20-Day Bollinger Upper Band | 23.00 |
| Beta | 2.24 |
| RSI | 49.98 |
| 50-Day SMA | 19.44 |
| 150-Day SMA | 13.83 |
| 200-Day SMA | 16.16 |
System |
|
| Modified | 5/3/2025 6:11:47 AM EST |